Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Post-Mkt 04-07 19:35:38 EDT

24.61

-0.28

-1.12%

盘后24.61

+0.000.00%

16:20 EDT

High24.80	Low23.93	Vol1.35M
Open24.78	D1 Closing24.89	Amplitude3.50%
Mkt Cap5.01B	Tradable Cap2.19B	Total Shares203.53M
T/O32.98M	T/O Rate1.52%	Tradable Shares89.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":24.61,"timestamp":1775592000000,"preClose":24.89,"halted":0,"volume":1351884,"hourTrading":{"tag":"盘后","latestPrice":24.61,"preClose":24.61,"latestTime":"16:20 EDT","volume":119987,"amount":2952881.749818,"timestamp":1775593200369,"change":0,"changeRate":0,"amplitude":0.000406},"delay":0,"changeRate":-0.011249497790277264,"floatShares":89017500,"shares":203532180,"eps":-2.679914,"marketStatus":"Post-Mkt","change":-0.28,"latestTime":"04-07 19:35:38 EDT","open":24.78,"high":24.8,"low":23.93,"amount":32978520.306622,"amplitude":0.034954,"askPrice":26.95,"askSize":10,"bidPrice":24.61,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.679914,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775606400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":24.89,"preHourTrading":{"tag":"盘前","latestPrice":25.5,"preClose":24.89,"latestTime":"07:11 EDT","volume":1,"amount":25.5,"timestamp":1775560297285,"change":0.61,"changeRate":0.024508,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":24.61,"preClose":24.61,"latestTime":"16:20 EDT","volume":119987,"amount":2952881.749818,"timestamp":1775593200369,"change":0,"changeRate":0,"amplitude":0.000406},"volumeRatio":0.986126,"impliedVol":0.5852,"impliedVolPercentile":0.616},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2625300069","title":"Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2625300069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625300069?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:15","pubTimestamp":1775564138,"startTime":"0","endTime":"0","summary":"Andy Chen, an analyst from Wolfe Research, maintained the Buy rating on Immunovant. The associated price target is $47.00. Andy Chen has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strengthening-the-buy-case-for-imvt-1402-targeted-phase-3-graves-disease-strategy-and-reproducible-efficacy-support-commercial-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strengthening-the-buy-case-for-imvt-1402-targeted-phase-3-graves-disease-strategy-and-reproducible-efficacy-support-commercial-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664954","title":"Immunovant CEO Eric Venker disposes of common shares worth $8.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664954","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664954?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:33","pubTimestamp":1775248420,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker reported acquisition of 368,750 common shares on April 1, 2026.Disposals totaled 349,189 common shares on April 1-2, 2026 at prices of $24.04-$25.10 per share.Directly owned common shares stood at 19,561 following transactions.Derivative holdings included 1,106,250 capped value appreciation rights after transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL60pZnM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","IMVT","BK4588","BK4585","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624860016","title":"Sector Update: Health Care Stocks Softer Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2624860016","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624860016?lang=en_us&edition=fundamental","pubTime":"2026-04-03 01:55","pubTimestamp":1775152549,"startTime":"0","endTime":"0","summary":"Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF  shedding 0.8%.The iShares Biotechnology ETF  fell 1.2%.In corporate news, Eli Lilly  and Novo Nordisk's  GLP-1 drugs included in President Trump's plan to extend coverage of weight-loss treatments for some Medicare beneficiaries would cost health insurers billions of dollars in its first year, Bloomberg reported, citing an analysis published in the Journal of the American Medical Association. Lilly shares were down 2.2%, and Novo was easing 0.1%.Grifols  faces new operating conditions across all of its Canadian plasma collection centers after Health Canada inspections found recurring, systemic compliance deficiencies, CBC News reported Wednesday, citing a spokesperson for the regulator. Grifols shares were down 0.5%.Immunovant  shares fell 1% after the company said topline results from two phase 3 clinical studies of batoclimab as an experim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2089984988.USD","LU2211815571.USD","LU2357305700.SGD","LU0122379950.USD","LU2168564495.EUR","LU1023059063.AUD","LU2462157665.USD","LU0964807845.USD","LU0234572021.USD","LU0689472784.USD","LU1057294990.SGD","LU2237438978.USD","IMVT","LU0820561818.USD","LU0889565916.HKD","LU2112291526.USD","GRFS","LU0823434740.USD","LU2491049909.HKD","LU2264538146.SGD","LU1064131342.USD","SG9999018865.SGD","LU2552382058.USD","IE00BJJMRX11.SGD","SGXZ81514606.USD","LU0316494557.USD","ELIS","LU1267930730.SGD","LU2360106947.USD","IE00BKDWB100.SGD","LU0354030511.USD","LU2491050154.USD","LU2756315318.SGD","LU2471134523.USD","LU0106261372.USD","LU2023250504.SGD","LU1623119135.USD","LU0320765992.SGD","LU0432979614.USD","LU1720051017.SGD","LU2602419157.SGD","IE00B1BXHZ80.USD","BK4599","LU1093756325.SGD","IE00BN29S564.USD","SGXZ51526630.SGD","LU2023250330.USD","BK4532","LU2896262040.SGD","LU1366192091.USD","NVO","LU2471134796.USD","LU0708995401.HKD","LU0640476718.USD","BK4533","LU2552382132.HKD","IE00BFSS7M15.SGD","LU2213496289.HKD","IE0009355771.USD","LU2111349929.HKD","LU1868837136.USD","LU0061475181.USD","LU2468319806.SGD","NVOX","LU2461242641.AUD","LU0353189680.USD","LU2491050071.SGD","LU1989771016.USD","LU1629891620.HKD","LU1061106388.HKD","ELIL","LU2265009873.SGD","LU2750360641.GBP","IE00BK4W5M84.HKD","LU0097036916.USD","LU1323610961.USD","LU0823434583.USD","LU0672654240.SGD","LU0823416689.USD","LU0096364046.USD","SG9999018857.SGD","LABU","LU2236285917.USD","LU0238689110.USD","LU2237443465.HKD","IE00BFSS8Q28.SGD","IE00BJJMRZ35.SGD","LU0385154629.USD","LU0266013472.USD","LU1868836757.USD","LU1974910355.USD","LU0320765059.SGD","SG9999015978.USD","SGXZ31699556.SGD","LU0289739699.SGD","LU2750360997.AUD","LU1804176565.USD","LU1988902786.USD","LU0158827948.USD","LU1868837300.USD","SG9999015952.SGD","LU0114720955.EUR","LU2023251221.USD","SG9999014898.SGD","LU2361045086.USD","LU2471134952.CNY","LLY","LU1551013425.SGD","LU2063271972.USD","IE00BJLML261.HKD","SG9999015945.SGD","IE00B1XK9C88.USD","LU0456855351.SGD","IE00BKVL7J92.USD","LU1127390331.HKD","LU2361044949.HKD","LU1035775433.USD","LU2417539215.USD","LU0787776722.HKD","LU0466842654.USD","BK4588","LU0471298777.SGD","IE00B2B36J28.USD","LLYX","LU0882574055.USD","LU2237443549.SGD","LU1069344957.HKD","LU0354030438.USD","BK7104","IE00BJT1NW94.SGD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","LU2271345857.HKD","LU2089283258.USD","XBI","LU2237443895.HKD","LU2361044865.SGD","IE0001KFT4U8.USD","LU2168564065.EUR","LU1868836914.USD","LLYZ","IE00BWXC8680.SGD","LLII","SG9999001176.USD","IE00BKPKM429.USD","NVOH","LU0820561909.HKD","IE0004445239.USD","LU0943347566.SGD","LU0471298694.HKD","SG9999001176.SGD","LU0154236417.USD","LU0256863811.USD","LU2168564149.EUR","IE00B7KXQ091.USD","LU1983299246.USD","LU2456880835.USD","BK4581","SG9999014906.USD","LU0417517546.SGD","SG9999013999.USD","LU1093756168.USD","SGXZ57979304.SGD","LU1548497426.USD","LU0882574139.USD","LU0225283273.USD","BK4007","IE0005OL40V9.USD","LU0210536198.USD","IE00B4JS1V06.HKD","LU2168563687.JPY","SG9999014880.SGD","LU2087625088.SGD","LU0158827781.USD","LU2552382215.SGD","LU0203202063.USD","LU1232071149.USD","LU1551013342.USD","BK4534","BK4585","LU2756315664.SGD","GB00BDT5M118.USD","LU2237443622.USD","IE0004445015.USD","IE00B4R5TH58.HKD","LU2028103732.USD","LU2237443978.SGD","LU1712237335.SGD","LU0058720904.USD","BK4516","LU1291159041.SGD","SG9999014914.USD","LU0786609619.USD","LU1917777945.USD","BK4139","IE00BJJMRY28.SGD","LU2108987350.USD","SG9999017495.SGD","IE0002141913.USD","LU1280957306.USD","LU2168564222.USD","LU0094547139.USD","LU2746668461.USD","IE00BZ1G4Q59.USD","LU0353189763.USD","LU1720051108.HKD","LU2089284900.SGD","LU0006306889.USD","LU0323591593.USD","LU0683600562.USD","LU2106854487.HKD","LU0820562030.AUD","LU2471134879.HKD","LU2237443382.USD","LU0109391861.USD","LU0079474960.USD","IE00B775H168.HKD","LU0203201768.USD","LU2324357040.USD","SG9999015986.USD","LU1868836591.USD","LU0109394709.USD","SGXZ99366536.SGD","LU1145028129.USD","LU0198837287.USD","LU2746668974.SGD","LU0256863902.USD","LU1814569148.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624688259","title":"Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2624688259","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624688259?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:35","pubTimestamp":1775144127,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Immunovant, with a price target of $50.00. Thomas Smith h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-maintained-on-immunovant-as-imvt-1402-pipeline-overshadows-batoclimab-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-maintained-on-immunovant-as-imvt-1402-pipeline-overshadows-batoclimab-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624264688","title":"Immunovant price target lowered to $50 from $52 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2624264688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624264688?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:31","pubTimestamp":1775143875,"startTime":"0","endTime":"0","summary":"Leerink analyst Thomas Smith lowered the firm’s price target on Immunovant (IMVT) to $50 from $52 and keeps an Outperform rating on the shares. The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-lowered-to-50-from-52-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-lowered-to-50-from-52-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IMVT","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624504321","title":"Sector Update: Health Care Stocks Decline Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2624504321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624504321?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:19","pubTimestamp":1775135950,"startTime":"0","endTime":"0","summary":"Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF  0.7% lower and the iShares Biotechnology ETF  down 1.6%.Immunovant  shares were down more than 10% after the company said topline results from two phase 3 clinical studies of batoclimab as an experimental treatment of thyroid eye disease in adults showed that they failed to meet their primary endpoint.Novo Nordisk  said its 25 mg Wegovy pill demonstrated \"significantly greater\" mean weight loss than Eli Lilly's  36 mg orforglipron, which was approved by the Food and Drug Administration under the brand name Foundayo. Shares of Novo Nordisk were down more than 1% pre-bell.Adagene  stock was down more than 15% after the company priced an underwritten public offering of about 18.7 million American depositary shares at $3.75 apiece, for gross proceeds of roughly $70 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2023250330.USD","LU0058720904.USD","IE00BKVL7J92.USD","IE00BKDWB100.SGD","LU2213496289.HKD","LU1291159041.SGD","LU2236285917.USD","LU0203201768.USD","LU2462157665.USD","LU1720051108.HKD","LU2087625088.SGD","IE00BFSS8Q28.SGD","LU1035775433.USD","LU0079474960.USD","LU1804176565.USD","LU1720051017.SGD","LU2750360641.GBP","ELIS","LU0323591593.USD","SGXZ51526630.SGD","LU2491050154.USD","LLY","LU2468319806.SGD","LU2756315318.SGD","XLV","LU0964807845.USD","IE00B7KXQ091.USD","LU1868836591.USD","SG9999014898.SGD","IE00BFSS7M15.SGD","LU1061106388.HKD","LU0683600562.USD","SGXZ31699556.SGD","LU2168563687.JPY","LU2108987350.USD","ELIL","LU0471298777.SGD","LU2552382215.SGD","LU0417517546.SGD","BK4007","LU2211815571.USD","NVOX","BK4516","LU1814569148.SGD","IE00B2B36J28.USD","SG9999017495.SGD","LLII","LLYX","LU2237443622.USD","LU2168564065.EUR","LU1974910355.USD","LU0238689110.USD","SG9999015952.SGD","LU2265009873.SGD","SG9999001176.SGD","LU0234572021.USD","LU0256863902.USD","LU0354030511.USD","LU0006306889.USD","LU1064131342.USD","LLYZ","BK7104","LU0096364046.USD","LU1093756168.USD","LU1551013425.SGD","IE0002141913.USD","LU0353189680.USD","LU0823416689.USD","LU0109394709.USD","LU0466842654.USD","LU1868837136.USD","LU0787776722.HKD","SG9999014914.USD","LU2746668974.SGD","LU0882574139.USD","LU0689472784.USD","LU2237443895.HKD","LU2111349929.HKD","IE00B1XK9C88.USD","LU1868836757.USD","LU2089984988.USD","BK4588","LU0823434583.USD","ADAG","LU0289739699.SGD","LU2471134879.HKD","BK4534","LU2168564149.EUR","LU2237443382.USD","BK4581","LU0097036916.USD","LU0353189763.USD","LU0354030438.USD","LU2471134952.CNY","IE00BFTCPJ56.SGD","LU1280957306.USD","LU2106854487.HKD","LU1868837300.USD","LU2089283258.USD","LU0432979614.USD","LU2471134523.USD","IE0004445239.USD","LU1145028129.USD","LU2491049909.HKD","LU0320765059.SGD","LU2756315664.SGD","LU2896262040.SGD","LU2237443978.SGD","LU0708995401.HKD","LU2237443549.SGD","LU1551013342.USD","LU2271345857.HKD","LU1712237335.SGD","BK4533","SG9999013999.USD","LU2089284900.SGD","LU0456855351.SGD","SG9999015986.USD","BK4585","IE0001KFT4U8.USD","SG9999001176.USD","LU0154236417.USD","LU2028103732.USD","LU0640476718.USD","BK4139","LU0210536198.USD","LU1983299246.USD","IE00BZ1G4Q59.USD","BK4532","SGXZ57979304.SGD","LU1989771016.USD","IE00B1BXHZ80.USD","LU0094547139.USD","LU0122379950.USD","SG9999014906.USD","SG9999018857.SGD","IE00BWXC8680.SGD","LU0203202063.USD","LU0320765992.SGD","IE00BJJMRX11.SGD","LU2361044949.HKD","SG9999014880.SGD","IE00BKPKM429.USD","LU2357305700.SGD","IE00B775H168.HKD","LU0158827781.USD","BK4599","LU1629891620.HKD","LU1917777945.USD","LU2602419157.SGD","LU2063271972.USD","LU0256863811.USD","LU0385154629.USD","LU1623119135.USD","IE0004445015.USD","LU2750360997.AUD","LU2746668461.USD","LU2471134796.USD","LU0672654240.SGD","LU2360106947.USD","IE00BJJMRZ35.SGD","LU0820562030.AUD","LU2023251221.USD","IE00B4R5TH58.HKD","LU2324357040.USD","LU0061475181.USD","IE0005OL40V9.USD","NVO","LU2168564495.EUR","IE00BJT1NW94.SGD","LU2023250504.SGD","SG9999015945.SGD","LU2456880835.USD","LU0889565916.HKD","LU1093756325.SGD","IE00BJJMRY28.SGD","NVOH","SGXZ99366536.SGD","LU1057294990.SGD","LU0823434740.USD","LU1323610961.USD","LU2361044865.SGD","LU2417539215.USD","IE00B4JS1V06.HKD","LU0943347566.SGD","LU1868836914.USD","LU2168564222.USD","LU2552382058.USD","IE0009355771.USD","LU2237443465.HKD","LU1232071149.USD","LU2112291526.USD","LU1988902786.USD","LU1548497426.USD","IBB","IE00BJLML261.HKD","LU0820561909.HKD","IE00BK4W5M84.HKD","LU1127390331.HKD","LU0198837287.USD","LU2552382132.HKD","SGXZ81514606.USD","LU0882574055.USD","LU2264538146.SGD","LU0109391861.USD","LU0158827948.USD","LU1267930730.SGD","LU2237438978.USD","LU0471298694.HKD","IE00BK4W5L77.USD","IMVT","SG9999018865.SGD","LABU","LU1366192091.USD","LU2491050071.SGD","LU2361045086.USD","LU0106261372.USD","GB00BDT5M118.USD","LU0114720955.EUR","LU0266013472.USD","LU0316494557.USD","IE00BN29S564.USD","LU1023059063.AUD","LU2461242641.AUD","XBI","LU1069344957.HKD","SG9999015978.USD","LU0820561818.USD","LU0786609619.USD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505605","title":"BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505605?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:36","pubTimestamp":1775129790,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocksWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e5355e74f3a6d8ed27a66eec612a1a71","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL6N40L0UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","SG9999014898.SGD","IE0001KFT4U8.USD","BK4548","IE00B7KXQ091.USD","LU0792757196.USD","LU1934455277.USD","LU0955669360.SGD","HMH","IE00B4YYXB79.USD","LU1917777945.USD","LU1868836914.USD","AALG","IE000MB6IJN5.SGD","LU2403377893.USD","BK4015","LU0742534661.SGD","IE00B7SZLL34.SGD","LU1720051017.SGD","LU0390134368.USD","BK4220","LU0724618789.USD","BK4559","IE0004445015.USD","SG9999015358.SGD","LU0345768740.USD","LU1084165304.USD","LU0878866978.SGD","LU2272731782.SGD","LU0980610538.SGD","IE00BJJMRY28.SGD","LU0971552673.USD","LU1074936037.SGD","BK4535","USAW.SI","BK4500","LU0648000940.SGD","LU1914381329.SGD","INO","LU1974910355.USD","LU1674673691.USD","LU1582986433.USD","LU2347655156.SGD","FCX","IE000YTNTUN2.SGD","LU1804176565.USD","LU2065170008.USD","LU2420271590.USD","LU0348723411.USD","LU0345777147.USD","LU0158827948.USD","LU0278409577.USD","LU1582987597.SGD","LU1302929846.USD","LU2552382215.SGD","LU1992135399.USD","LU1267930573.SGD","LU2129689514.USD","LU0690374961.EUR","LU0708995401.HKD","LU2404859667.USD","IE0004086264.USD","LU0289941410.SGD","LU0265550946.USD","IE00B19Z9P08.USD","IE00BGHQF524.EUR","LU2087621335.USD","DAL","LU2087625088.SGD","LU2065171402.SGD","LU1633808545.USD","BK4516","AMZZ","LU2242650005.HKD","LU0433182093.SGD","LU1366334651.USD","LU0823421416.USD","IE0034235303.USD","LU0122376428.USD","LU0310800379.SGD","LU1868836591.USD","LU0161305163.EUR","SGXZ81514606.USD","LU0251142724.SGD","LU0572108347.SGD","LU1130305938.SGD","AAL","BK4209","LU0786609619.USD","LU2430703178.SGD","BK4566","SG9999015986.USD","BK4570","SGXZ99366536.SGD","IE000KEQY171.SGD","LU0345770308.USD","LU2361044865.SGD","SGXZ31699556.SGD","LU1880398471.USD","LU1732800096.USD","SG9999015945.SGD","LU1116320901.HKD","LU0300736492.USD","LU0345774391.USD","IE00B3S45H60.SGD","LU0965509283.SGD","LU0068578508.USD","BK4201","LU0320765059.SGD","LU0654597011.USD","LU1046421795.USD","LU2592432038.USD","LU2168564222.USD","SG9999002232.USD","LU1323610961.USD","LU2237438978.USD","LU0075056555.USD","LU2452424414.USD","LU1435385759.SGD","SG9999018865.SGD","IE00B19Z3581.USD","LU2023250504.SGD","LU0054578231.USD","LU0154245756.USD","LU0788109477.HKD","BK4558","LU2065169927.USD","LU0210528500.USD","LU2108987350.USD","LU1429558221.USD","EL","LU1489326972.SGD","XOMZ","BK4561","SCCO","IE00BK4W5M84.HKD","LU0496367417.USD","LU2264538146.SGD","LU1162221912.USD","LU1929549753.HKD","LU0077335932.USD","IE00BZ1G4Q59.USD","IE000WAW04H5.SGD","LU0082616367.USD","LU2111349929.HKD","HL","DVN","LU0912757837.SGD","LU0345769631.USD","LU1548497426.USD","LU2552382058.USD","LU0256863902.USD","LU2125154778.USD","LU1935042488.USD","LU0138981039.USD","LU2168564065.EUR","LU0198837287.USD","SG9999014906.USD","LU0211327993.USD","LU2487616109.SGD","IE00B1XK9C88.USD","BK4139","IE00BJTD4N35.SGD","LU1935043023.USD","LU0965509010.AUD","LU0354030511.USD","AMZY","LU0985320562.USD","LU0011850046.USD","LU0316494557.USD","LU0353189763.USD","LU1366333091.USD","SG9999014914.USD","LU0572940350.SGD","LU0203201768.USD","LU1309081286.SGD","LU0957791311.USD","XOM","IE000BZT7R73.USD","LU1778281490.HKD","BK4612","LU0787776722.HKD","LU2054465674.USD","IE0004091025.USD","LU2471134523.USD","LU1366192091.USD","SG9999017495.SGD","HK0000914660.USD","IE00B5949003.HKD","NWMX","LU0820561818.USD","LU2430703251.USD","IE00BYQQ9H92.USD","LU0157215616.USD","IMVT","IE00BFXG0V08.USD","BK4008","LU0345781412.USD","LU0050427557.USD","LU0823434583.USD","LU2750360997.AUD","LU2860962120.EUR","BK4532","LU0080751232.USD","IE00BFSS8Q28.SGD","LU0175139822.USD","LU1430597077.USD","IE00BJLML261.HKD","LU2265009873.SGD","LU1935043536.SGD","LU0498741890.SGD","BK4504","LU0320765489.SGD","LU2764262908.HKD","LU0256331488.USD","LU2133065610.SGD","LU0154245673.USD","LU0985489474.SGD","LU1119994496.HKD","SG9999000418.SGD","LU2756315664.SGD","IE00BZ9MQY76.HKD","LU1223083913.SGD","LU1935042991.SGD","LU0612318971.USD","SG9999018857.SGD","BK5111","LU0264606111.USD","LU2129689431.USD","IE000ITXATA3.USD","CVX","BK4543","IE00B19Z3B42.SGD","IE00BMPRXQ63.HKD","AZYY","CDE","LU2065171311.SGD","LU0238689110.USD","LU1674673428.USD","LU0795875086.SGD","BHP","LU2463028550.USD","WING","LU2505996681.GBP","LU0276348264.USD","IE00B5TLWC47.USD","LU0791591158.USD","LU0345769128.USD","IE00B3SWFQ91.USD","LU0070302665.USD","IE00BKPKM429.USD","LU0208291251.USD","BK4583","LU0630314457.HKD","LU0642271901.SGD","LU1078025761.USD","LU1267930490.SGD","SG9999002224.SGD","LU2764263203.CNY","IE00BJJMRX11.SGD","XOMO","LU0096362180.USD","LU2381873111.SGD","BK4554","LU1823568750.SGD","LU0053666078.USD","IE00B4JS1V06.HKD","LU1037948541.HKD","LU0127658192.USD","LU2213496289.HKD","SG9999014880.SGD","LU0788109121.HKD","LU1880398554.USD","IE00BMPRXN33.USD","LU2362540622.SGD","LU2129689605.HKD","LU2404859741.USD","LU2097829019.USD","LU2089284900.SGD","LU2552382132.HKD","LU0234572021.USD","LU0965509101.SGD","BK4507","LU0070217475.USD","BK4179","LU1046248800.SGD","LU0267386448.USD","BK4089","LU0689472784.USD","LU1582986359.USD","HK0000914686.HKD","LU0109391861.USD","LU1127390331.HKD","IE00BQXX3F31.USD","LU2237957902.USD","LU2028103732.USD","SG9999014542.SGD","IE00BQXX3C00.GBP","LU1551013425.SGD","LU0823434740.USD","LU1150488218.USD","LU2471134952.CNY","SG9999014567.USD","IE0009356076.USD","LU0368265764.SGD","IE00B19Z8W00.USD","LU2360032135.SGD","IE0002270589.USD","LU1582987324.SGD","LU2543165471.USD","SG9999015341.SGD","BK4213","LU0612318385.USD","IE00B19Z9505.USD","LU2602419157.SGD","LU1496350171.SGD","LU1839511570.USD","LU2896262040.SGD","LU0943347566.SGD","LU1035775433.USD","LU1023059493.AUD","IE00B894F039.SGD","LU2168564149.EUR","LU0648001328.SGD","LU0640476718.USD","LU1066053197.SGD","LU1791710582.SGD","LU1150488135.SGD","IE000F7OJYX1.SGD","LU1223082196.USD","LU0690374615.EUR","LU1201861249.SGD","LU1267930730.SGD","LU0055631609.USD","LU0898667661.SGD","LU2505996509.AUD","LU0096364046.USD","LU0820561909.HKD","LU2272731600.USD","LU2361044949.HKD","LU0889565833.HKD","LU0882574139.USD","LU0072461881.USD","LU0251131958.USD","LU2326559502.SGD","LU1691799644.USD","IE00BFMHRM44.USD","LU2271345857.HKD","BK7511","SGXZ23171101.USD","IE000SO60NU8.SGD","UAL","LU0456854461.SGD","BK4527","LU1988902786.USD","LU0215105999.USD","LU1814569148.SGD","LU1861127337.USD","IE00BN29S564.USD","LU1989764748.USD","IE00BQXX3D17.EUR","LU2106854487.HKD","LU0708994859.HKD","LU2247934214.USD","LU0211328371.USD","LU0072462426.USD","LU0683600562.USD","LU1201861165.SGD","LU0345780521.USD","LU1066051811.HKD","LU0823411888.USD","LU0528227936.USD","NEMG","BK4551","LU1244550494.USD","LU0788109394.HKD","IE0000B7K699.USD","LU0052756011.USD","IE00B3CCJ963.GBP","CLDX","NEM","IE00BKVL7J92.USD","LU0572939691.SGD","LU1992135472.HKD","LU0210533765.USD","IE00B19Z9Z06.USD","LU0310800965.SGD","LU0210536198.USD","IE00B1BXHZ80.USD","LU1496350502.SGD","LU1803068979.SGD","LU0942090050.USD","LU1629891620.HKD","BK4533","BK4581","LU0368265418.SGD","LU1861558580.USD","BK4017","LU1934455863.HKD","LU0494093205.USD","BK4579","LU0330918003.SGD","LU1267930813.SGD","LU2471134796.USD","LU0417517546.SGD","AMZU","LU1066051225.USD","IE00BFXG1179.USD","LU0323591593.USD","LU1069344957.HKD","LU1883866441.USD","OXY","LU0820562030.AUD","LU2764263039.SGD","LU2417539215.USD","BK7095","LU0256863811.USD","IE00B3M56506.USD","LU0354030438.USD","LU0498741114.HKD","LU1852331112.SGD","BK4585","LU1244550221.USD","LU2092937148.SGD","IE00BQJZX424.USD","LU1861559042.SGD","LU1316542783.SGD","LU0868494617.USD","LU2456880835.USD","LU2463526074.USD","LU0130102774.USD","LU0149725797.USD","LU1232071149.USD","BK4127","IE00BK4W5L77.USD","LU0312595415.SGD","LU1153585028.USD","IE00BJTD4V19.USD","LU1244550577.SGD","LU2077746001.SGD","LU1934455194.USD","LU2357305700.SGD","GSAT","IE00BWXC8680.SGD","IE00B2Q91V27.USD","LU1718418525.SGD","LU0353189680.USD","SG9999014575.USD","LU0170899867.USD","LU1261432733.SGD","LU2236285917.USD","AMZD","LU0107464264.USD","LU0672654240.SGD","LU0300736062.USD","LU0203347892.USD","BK4596","LU2471134879.HKD","LU0868494708.USD","LU0965508806.USD","LU1551013342.USD","SGXZ51526630.SGD","LU0466842654.USD","BK4588","IE0034235071.USD","IE00BKDWB100.SGD","SG9999001077.SGD","SG9999004303.SGD","SG9999015952.SGD","LU0251132253.USD","LU0171293334.USD","LU0072463663.USD","LU1815333072.USD","LU0964807845.USD","LU0345768153.USD","IE0003U64NQ7.SGD","BK4534","LU0128525689.USD","LU2720916845.USD","LU0345770993.USD","LU0132412106.USD","BK4122","BK4547","LU0098860793.USD","LU1868836757.USD","LU1280957306.USD","IE00BMPRXR70.SGD","LU1267930227.SGD","LU0203345920.USD","LU0823421333.USD","LU0266512127.USD","LU1145028129.USD","LU2092627202.USD","LU1037948897.HKD","LU0308772762.SGD","LU2125154935.USD","LU0048573561.USD","IE0005OL40V9.USD","LU1064927863.SGD","LU0097036916.USD","LU1883839398.USD","LU2168563687.JPY","LU2430703095.HKD","SG9999002521.SGD","RIO","LU1064131342.USD","LU1366334578.USD","LU0053671581.USD","LU1894683348.USD","BK4550","BK7507","LU0788109048.HKD","LU1868837300.USD","LU0456855351.SGD","LU2065731478.USD","LU2168564495.EUR","LU2317271919.USD","GFI","IE00B775SV38.USD","LU0302445910.USD","IE00B19Z8X17.USD","LU1894683264.USD","IE00B775H168.HKD","LU0345780281.USD","SG9999015978.USD","LU2023250330.USD","LU0342679015.USD","LU0971552830.HKD","LU0211331839.USD","LU2250418816.HKD","LU2023250843.SGD","IE0004445239.USD","LU2362541273.HKD","LU0724617625.USD","SG9999001440.SGD","LU2746668461.USD","LU0079474960.USD","SG9999001143.SGD","LU0310799852.SGD","BK4503","IE00BFSS7M15.SGD","IE00BWDBJ516.SGD","LU0154236417.USD","LU2461242641.AUD","LU2360106780.USD","GB00BDT5M118.USD","LU0130103400.USD","LU2275660780.HKD","BK4568","LU2756315318.SGD","LU1223082519.USD","LU2211817866.USD","LU0109392836.USD","LU0056508442.USD","LU0861579265.USD","LU0345780950.USD","LU0314104364.USD","BK4592","LU0719512351.SGD","LU0345777659.USD","LU0889566641.SGD","LU2237957811.SGD","AMZP","LU0265550359.USD","LU0791590937.USD","AMZW","LU1935042215.USD","BK4598","LU2362541513.USD","LU0061475181.USD","LU0234570918.USD","LU0345774631.USD","LU0048584097.USD","IE0009G5SDU7.USD","LU1791710400.SGD","LU0011963245.USD","LUV","IE000W1ABFV2.USD","LU1116320737.USD","LU2462611646.USD","HLXX","LU2498475776.HKD","LU2750360641.GBP","LU0795875169.SGD","XOMX","LU2242649171.HKD","BK4524","LU0162691827.USD","LU0788108826.HKD","LU1732799900.SGD","LU2211815571.USD","BK4183","LU0831103253.SGD","LU0266512473.USD","LU1720051108.HKD","LU2063271972.USD","LU0061474960.USD","LU0128525929.USD","LU2746668974.SGD","BK4210","LU2023251221.USD","LU2089283258.USD","LU0203202063.USD","LU0029864427.USD","LU0320765646.SGD","LU0061474705.USD","LU0158827781.USD","BK4538","LU1989764664.SGD","SG9999014559.SGD","LU0289960550.SGD","LU0505663152.USD","LU1066051498.USD","LU2462157665.USD","FCXG","LU2083900584.USD","IE000M9KFDE8.USD","LU2361045086.USD","AMZN","BK4007","LU1235294995.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624572906","title":"Immunovant reports batoclimab clinical studies missed primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2624572906","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624572906?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:11","pubTimestamp":1775121085,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) reported the topline results from its two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-reports-batoclimab-clinical-studies-missed-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-reports-batoclimab-clinical-studies-missed-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624782574","title":"Immunovant Shares Fall 16% Premarket After Co's Treatment for Eye Disease Fails Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624782574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624782574?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:08","pubTimestamp":1775120921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L0PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624749195","title":"Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2624749195","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624749195?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120441,"startTime":"0","endTime":"0","summary":"Immunovant reported topline results from two Phase 3 studies of batoclimab in thyroid eye disease, with results already presented in this update.Both trials missed primary endpoint, raising uncertainty around batoclimab commercial prospects in thyroid eye disease.Safety profile matched prior studies, with no new safety signals flagged.Immunovant shifted emphasis to IMVT-1402 development across autoimmune diseases, with Graves’ disease positioned as key priority.Topline data from potentially registrational IMVT-1402 studies in Graves’ disease expected in calendar year 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3Mp9Mk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","BK4139","SG9999014005.SGD","IE00BN0W2W23.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4585","BK4112","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IMVT","SG9999014021.USD","ROIV","LU2210149790.SGD","SG9999014013.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574989","title":"Immunovant Inc - to Review Future Plans for Batoclimab Development With Hanall Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574989?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA1YZQTH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574987","title":"Immunovant Inc - Topline Data From Imvt-1402 Graves’ Disease Studies Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574987?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA1YZQTH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574983","title":"Immunovant Inc - Batoclimab in Ted Shows No New Safety Signals in Phase 3 Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574983","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574983?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA1YZQTH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574572","title":"Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624574572?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:00","pubTimestamp":1775120400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA1YZQTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMVT","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624456597","title":"Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624456597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624456597?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:57","pubTimestamp":1775041074,"startTime":"0","endTime":"0","summary":"In a report released today, from Wells Fargo maintained a Buy rating on Immunovant, with a price target of $45.00. In addition to Wells Fargo, Immu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739398","title":"Bernstein initiates Immunovant with a Market Perform, $28 price target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739398?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:50","pubTimestamp":1774011025,"startTime":"0","endTime":"0","summary":"As previously reported, Bernstein analyst William Pickering initiated coverage of Immunovant (IMVT) with a Market Perform rating and $28 price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bernstein-initiates-immunovant-with-a-market-perform-28-price-target-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bernstein-initiates-immunovant-with-a-market-perform-28-price-target-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620725052","title":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of USD 5.65 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620725052","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620725052?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:37","pubTimestamp":1773959842,"startTime":"0","endTime":"0","summary":"Eric Venker, President and Immunovant CEO, reported a change in beneficial ownership of Roivant common shares dated 03/17/2026.He acquired 200,000 common shares at USD 3.85 per share through an option exercise.Venker sold 200,000 common shares at USD 28.24 per share.Directly held common shares after the transactions totaled 1,647,546.Stock options beneficially owned after the transaction totaled 4,844,834.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4w0c0y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4588","BK4139","BK4585","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612427295","title":"Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612427295","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612427295?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:57","pubTimestamp":1771455468,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8Yrs1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","ROIV","BK4139","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610606496","title":"Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610606496","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610606496?lang=en_us&edition=fundamental","pubTime":"2026-02-11 10:05","pubTimestamp":1770775537,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Immunovant, with a price target of $49.00. Accord...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-immunovant-imvt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610203196","title":"Immunovant (IMVT) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610203196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610203196?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:35","pubTimestamp":1770744915,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Immunovant, with a price target of $54.00. According to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IMVT","BK4139","BK4127","OPY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":0.0569},{"period":"1month","weight":-0.0664},{"period":"3month","weight":-0.039},{"period":"6month","weight":0.5484},{"period":"1year","weight":0.7071},{"period":"ytd","weight":-0.0208}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.022352},{"month":5,"riseRate":0.333333,"avgChangeRate":0.069275},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.068981},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040449},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction